About: COVID-19 Pandemic: A Case for Phytomedicines

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 Pandemic: A Case for Phytomedicines Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 Pandemic: A Case for Phytomedicines
Creator	Ade-Ademilua, Omobolanle Agunbiade, Foluso Akindele, Abidemi Akinleye, Moshood Asekun, Olayinka Awodele, Olufunsho Ishola, Ismail Odukoya, Olukemi Orabueze, Ifeoma Oreagba, Ibrahim Salu, Olumuyiwa Sofidiya, Margaret Sowemimo, Abimbola
Source	PMC
abstract	Coronavirus disease 2019 (COVID-19) is an infection caused by a newly discovered coronavirus which was identified in Wuhan, China. The race is on globally to repurpose drugs for COVID-19 and develop a safe and effective vaccine against the disease. There is an urgent need to search for effective remedies against COVID-19 from the rich and extensive flora of Africa and the world. A literature search was conducted to obtain information on drugs with the potential for effectiveness in the treatment of COVID-19 based mostly on outcomes of preclinical studies and a few clinical investigations. This was considered important to this perspective as some of the identified mechanisms of action may be related to potential anti-COVID-19 actions of phytomedicines. The findings from the literature search were also used to establish the need for exploration of phytomedicines in the fight against COVID-19. This perspective identifies the need to preserve the rich tradition of herbal medicine in Africa, repositioning it by inculcating all aspects of discovery, development, and chemical evaluation of pharmaceuticals from medicinal plants for effective management of prevalent diseases. The identified mechanisms of action of current drugs under consideration for the treatment of COVID-19 include preventing fusion of SARS-CoV-2 with human cells; decrease acidity in endosomes, cell membrane-derived vesicles for transportation of the virus within the host cell and within which the virus can replicate; and blockade of the production of proinflammatory cytokines. Phytomedicines may possibly elicit either one or a combination of these effects. The case for the exploration of phytomedicines against COVID-19 is strengthened by the emergence of a number of conventional drugs from medicinal plants and the emergence of botanicals with proven efficacy for some medical conditions. Caution against indiscriminate use of medicinal plants in the guise of treating COVID-19 has been highlighted and the need for reliable preclinical and clinical studies.
has issue date	2020-08-14(xsd:dateTime)
bibo:doi	10.1177/1934578x20945086
has license	cc-by-nc
sha1sum (hex)	54b8f29a0d6dff2cbe18649bf919765b94809ac0
schema:url	https://doi.org/10.1177/1934578x20945086
resource representing a document's title	COVID-19 Pandemic: A Case for Phytomedicines
has PubMed Central identifier	PMC7429914
schema:publication	Nat Prod Commun
resource representing a document's body	covid:54b8f29a0d6dff2cbe18649bf919765b94809ac0#body_text
is schema:about of	named entity 'effective' named entity 'COVID-19' named entity 'repurpose' named entity 'virus' named entity 'disease' named entity 'Coronavirus disease 2019' named entity 'Africa' named entity 'COVID-19' named entity 'Pandemic' named entity 'MANAGEMENT' named entity 'REPOSITIONING' named entity 'EITHER' named entity 'FIGHT' named entity 'ELICIT' named entity 'CONVENTIONAL' named entity 'ACIDITY' named entity 'The race' named entity 'globally' named entity 'conducted' named entity 'effective' named entity 'aspects' named entity 'cell' named entity 'mechanisms' named entity 'consideration' named entity 'preventing' named entity 'COVID-19' named entity 'host cell' named entity 'Africa' named entity 'Africa' named entity 'COVID-19' named entity 'COVID-19' named entity 'COVID' named entity 'cell membrane' named entity 'COVID-19' named entity 'clinical investigations' named entity 'proinflammatory cytokines' named entity 'COVID-19 Pandemic' named entity 'based' named entity 'effectiveness' named entity 'infection' named entity 'meta-analysis' named entity 'scabies' named entity 'diarrheal diseases' named entity 'Africa' named entity 'Africa' named entity 'hydroxychloroquine' named entity 'herbal medicine' named entity 'Cameroon' named entity 'SARS-CoV-2' named entity 'WHO' named entity 'ribavirin' named entity 'Nigeria' named entity 'quality control' named entity 'Paracelsus' named entity 'scientific investigations' named entity 'Nigeria' named entity 'Egypt' named entity 'Favipiravir' named entity 'United States' named entity 'Algeria' named entity 'NHC' named entity 'hygiene' named entity 'COVID-19' named entity 'osteoarthritis' named entity 'vaccines' named entity 'Sudan' named entity 'Africa' named entity 'Middle East respiratory syndrome' named entity 'Africa' named entity 'pharmacokinetic' named entity 'Yaba'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software